Search - tctmd.com

Displaying 521 - 540 of 853

Sort: Relevancy | Date

News Daily News

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Michael O'Riordan

January 22, 2020

News Daily News

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

L.A. McKeown

January 21, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

L.A. McKeown

January 17, 2020

News Daily News

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Michael O'Riordan

January 16, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Aspirin Not Protective Against CVD in Black Patients

Caitlin E. Cox

December 18, 2019

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Yael L. Maxwell

December 12, 2019

News Daily News

Poor Exercise Capacity on Stress Echo in Women Predicts Death From CVD

Michael O'Riordan

December 10, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Testosterone Therapy Ups VTE Risk, Even When Indicated

Caitlin E. Cox

November 12, 2019

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Caitlin E. Cox

October 21, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

Bulimia May Contribute to Premature CVD in Women

L.A. McKeown

October 18, 2019

Advertisement

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Pot Talk: Review Urges Cardiologists to Discuss Marijuana Use

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

Pricey, Unproven ‘Executive’ CVD Screening the Norm at Top US Hospitals

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Aspirin Not Protective Against CVD in Black Patients

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

FDA Approves Icosapent Ethyl for Reducing CVD Events

‘Stronger’ Evidence That High Lp(a) Concentrations Cause CVD

Poor Exercise Capacity on Stress Echo in Women Predicts Death From CVD

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Grief and CVD: Simple Regimen May Lower Risk

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Testosterone Therapy Ups VTE Risk, Even When Indicated

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Bulimia May Contribute to Premature CVD in Women

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content